Overview

GLPG-0492, also known as MK-4541, is a non-steroidal selective androgen receptor modulator (SARM) originally developed by Galapagos NV in collaboration with Merck. It was designed to selectively activate androgen receptors in muscle and bone tissue while minimizing androgenic effects on the prostate, skin, and other androgen-sensitive organs. This tissue-selective profile makes it a candidate for treating sarcopenia, cachexia, and other muscle-wasting disorders.

In preclinical studies, GLPG-0492 demonstrated potent anabolic activity, increasing lean muscle mass and grip strength in animal models of muscle atrophy. Its selectivity was confirmed by a significantly higher ratio of anabolic to androgenic activity compared to testosterone. The compound also showed oral bioavailability, making it more convenient than injectable anabolic agents. Early-phase clinical trials evaluated its safety and pharmacokinetics in healthy volunteers.

GLPG-0492 belongs to the broader class of SARMs that includes compounds like RAD-140, LGD-4033, and Ostarine. Compared to steroidal androgens, SARMs like GLPG-0492 are being investigated for their potential to provide muscle- and bone-building benefits without the full spectrum of androgenic side effects. Development status and clinical progress should be verified, as pharmaceutical pipelines evolve over time.

Mechanism of Action

GLPG-0492 is a non-steroidal selective androgen receptor modulator (SARM) developed by Galapagos NV for the treatment of muscle wasting conditions such as sarcopenia and cachexia. Its primary mechanism involves binding to the androgen receptor (AR) in the cytoplasm, causing the receptor to undergo a conformational change, dissociate from heat shock proteins, dimerize, and translocate to the nucleus where it binds to androgen response elements (AREs) on target gene promoters.

The tissue selectivity of GLPG-0492 arises from the unique three-dimensional conformation it induces in the AR upon binding. In skeletal muscle cells (myocytes), this conformation promotes recruitment of co-activator proteins that drive transcription of anabolic genes involved in protein synthesis and muscle growth. In contrast, in prostate and other reproductive tissues, the same AR conformation leads to minimal co-activator recruitment or preferential co-repressor binding, resulting in negligible androgenic stimulation.

GLPG-0492 may additionally inhibit muscle protein breakdown through negative interference with the NF-κB signaling pathway, which regulates catabolic gene expression including components of the ubiquitin-proteasome system. Unlike traditional anabolic steroids, GLPG-0492 is not a substrate for 5α-reductase (which converts testosterone to the more potent DHT) or aromatase (which converts androgens to estrogens), further contributing to its favorable tissue-selective profile with reduced side effects on the prostate, skin, and lipid metabolism.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: GLPG-0492 (Selective Androgen Receptor Modulator)

Common Side Effects

• Headache and mild fatigue reported in early-phase clinical trials
• Mild transaminase elevations (ALT/AST) indicating hepatic stress
• Gastrointestinal discomfort (nausea, dyspepsia)
• Transient changes in lipid profiles (decreased HDL cholesterol)
• Mild acne or oily skin due to androgenic activity

Serious Adverse Effects

• Hepatotoxicity: Dose-dependent liver enzyme elevations; rare cases of significant hepatic injury in SARM class
• Cardiovascular risk: Suppression of HDL cholesterol; long-term cardiovascular outcomes unknown
• Hormonal suppression: May suppress endogenous testosterone production, leading to hypogonadal symptoms
• Thromboembolic events: Theoretical risk based on androgen receptor modulation class effects
• Long-term safety data are limited as this compound has not progressed beyond early clinical trials

Contraindications

• Known or suspected prostate or breast cancer (hormone-sensitive malignancies)
• Active liver disease or baseline transaminase elevations >2x ULN
• Pregnancy and lactation (teratogenic potential based on mechanism)
• Women of childbearing potential without reliable contraception
• History of venous thromboembolism
• Concurrent use of other androgenic or anabolic agents

Drug Interactions

• CYP3A4 substrates/inhibitors: GLPG-0492 metabolism may involve CYP enzymes; co-administration with strong CYP3A4 inhibitors (ketoconazole, ritonavir) may increase exposure
• Anticoagulants: SARMs may potentiate warfarin effects; monitor INR closely
• Insulin/hypoglycemics: May alter glucose metabolism; monitor blood sugar
• Other SARMs or anabolic steroids: Additive hormonal suppression and hepatotoxicity risk
• Corticosteroids: Combined use may increase risk of metabolic side effects

Population-Specific Considerations

• Women: Virilization risk (deepening voice, hirsutism, clitoral enlargement); avoid in pregnancy
• Elderly: May benefit from muscle-wasting indications, but cardiovascular and hepatic risks require careful monitoring
• Adolescents: Strictly contraindicated; risk of premature epiphyseal closure and hormonal disruption
• Hepatic impairment: Contraindicated or requires significant dose reduction with close LFT monitoring
• Renal impairment: Limited data; use with caution

Pharmacokinetic Profile